U.S. Markets open in 29 mins.

Arena Pharmaceuticals, Inc. (ARNA)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
25.75+0.66 (+2.63%)
At close: 4:00PM EDT
People also watch
VVUSOREXARIAKERXAMRN
  • D
    Dan
    Dan
    After a 40% drop in price of stock the courts have decided the following based on the companies omitting or nondisclosure.
    Therefore, the court concluded, the shareholders allege facts that were sufficient to show a material misrepresentation. In practice, that almost certainly means Arena will have to settle the suit.
    This is a potential 600 to 900 million dollar settlement
  • t
    tommy
    tommy
    Losing 2Billion in mcap in just 5 years. Extremely poor long performance. And only drug had royalty cut by 69%! Oh, my.
  • R
    Reza
    Reza
    Friends, received this from a savvy WSer "last time Belviq Company had 35M+shares outstanding was in 2005" striking that after 12 dilutions and a RS since 2009 we have 39M+today. Thurs Sept 21, 2017 saw 56% of trades shorting and on Friday Sept 22 55% of trades shorted
  • A
    Andy B
    Andy B
    Sales of ARNA's only drug, a flop diet pill, cant sustain daily operations, legal expenses, and pipe development
  • A
    Andy B
    Andy B
    Hey did any of you read the court's Oct 2016 class action ruling. now people authorized to settle must attend conferences. not looking pretty
  • A
    Andy B
    Andy B
    the Belviq Company...that's it
  • A
    Andy B
    Andy B

    Telling a Half-Truth Doesn't Work for Drugmaker ARNA
    The answer isn’t hiding information, either.
    https://www.bloomberg.com/view/articles/2016-10-28/telling-a-half-truth-doesn-t-work-for-arena-pharmaceuticals

    Telling a Half-Truth Doesn't Work for Drugmaker
    The answer isn’t hiding information, either.
    www.bloomberg.com
  • A
    Andy B
    Andy B
    Dilution to settle lawsuits...not a good thing
  • A
    Andy B
    Andy B
    Losing 2Billion in mcap in just 5 years. Extremely poor long performance. And only drug had royalty cut by 69%! Oh, my.
  • g
    gil
    gil
    $135 ( 13.5 ) to $25.64 ( $2.564) in a bull market means shorts are losing their pants and longs are winners...for arnatards
  • J
    Jay J
    Jay J
    Material Misrepresentation! Looks like settlement could cause bankruptcy
  • F
    FP
    FP
    The Dilution Co. fits
  • D
    Dan
    Dan
    Dead Rat Stock ... another 1,000 short at 25.90
    After a 40% drop in price of stock the courts have decided the following based on the companies omitting or nondisclosure.
    Therefore, the court concluded, the shareholders allege facts that were sufficient to show a material misrepresentation. In practice, that almost certainly means Arena will have to settle the suit.
    This is a potential 600 to 900 million dollar settlement
  • A
    Andy B
    Andy B
    Sales of ARNA's only drug cant sustain daily operations, legal expenses, and pipe development
  • A
    Andy B
    Andy B
    the company and it's 6 IB's throwing a lot of money to keep it propped up ahead of the dilution
  • R
    Romel
    Romel
    Looks like super low volume pps games by the 6 investment banks to trick you to buy. Anything you buy can and will be used against you. Not enough cash or revs to get all compounds through research and to FDA. Which research drug will be stopped? Only drug expecting 77% revenue decline 3Q. Dilution will be the solution! Don't fall for underwriter tricks. DYODD
  • A
    Andy B
    Andy B
    ARNA longs and pumpers rejoice in 20 years of unprofitability. Give high fives on having just 1 approved drug, a very poor selling diet pill, in 20 years. Dance about dilutions being life source. Raise their arms in the air rejoicing in their losses as only insiders and the lawyers defending against the Investor Class Action Suit make millions
  • D
    Dan
    Dan
    Pumpers asking if I'm with a Hedge fund is a big clue on who is getting paid on here. These pumpers try hard to hide the truth
  • A
    Andy B
    Andy B
    If you were pumping a 20 year old stock with had no profits. losses, dilutions and a flop diet pill you'd hide the truth too
  • A
    Andy B
    Andy B
    This co. has only 1 drug. A poor selling, marginal diet aid. It's their only revenue source. Arna has been heavily diluted. It's a low quality junk stock mostly held by small retail who put way too much money into it and are now desperately underwater.